

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-31 (canceled).

32. (currently amended) An isolated human polypeptide compound, which inhibits the interaction between PAP1 and parkin, having an amino acid sequence of at least 95% identity to the full length human-PAP1 sequence of SEQ ID NO: 2.

Claims 33-38 (canceled).

39. (previously presented) An isolated peptide or polypeptide comprising the amino acid sequence of SEQ ID NO. 2.

Claims 40-52 (canceled).

53. (currently amended) A composition comprising a polypeptide compound as claimed in claim 32, and a pharmaceutically acceptable vehicle or excipient.

Claims 54-58 (canceled).

59. (currently amended) A composition comprising a polypeptide compound as claimed in claim 32, and a carrier.

Claims 60-65 (canceled).

66. (new) A composition comprising a peptide or polypeptide as claimed in claim 39, and a pharmaceutically acceptable vehicle or excipient.

67. (new) A composition comprising a peptide or polypeptide as claimed in claim 39, and a carrier.